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Abstract Stem cell therapy opens a new window in medicine to overcome several diseases that remain incurable. It
appears such diseases as cardiovascular disorders, brain injury, multiple sclerosis, urinary system diseases, cartilage lesions
and diabetes are curable with stem cell transplantation. However, some questions related to stem cell therapy have
remained unanswered. Stem cell imaging allows approval of appropriated strategies such as selection of the type and dose
of stem cell, and also mode of cell delivery before being tested in clinical trials. MRI as a non-invasive imaging modality
provides proper conditions for this aim. So far, different contrast agents such as superparamagnetic or paramagnetic
nanoparticles, ultrasmall superparamagnetic nanoparticles, fluorine, gadolinium and some types of reporter genes have
been used for imaging of stem cells. The core subject of these studies is to investigate the survival and differentiation of
stem cells, contrast agent’s toxicity and long term following of transplanted cells. The promising results of in vivo and
some clinical trial studies may raise hope for clinical stem cells imaging with MRI.
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1 Introduction
The administration of stem cells opens a new window on
regenerating many damages in different tissues. The stem
cells are capable of self-renew and repairing the damaged
tissues with minimal side effects. In spite of promises for
regenerative medicine, the stem cell therapy most often are
still in the experimental stages, and needs to overcome
some challenges before clinical application. However,
concerns about some side effects such as failures of cellular
therapy remain as important challenges for stem cell
therapy. The most important concerns related to thera-
peutic applications of regenerative medicine include the
selection of an appropriated stem cell type, delivery route
of stem cells, and dosing regimen. Also, several questions
regarding the biology of stem cells in living subjects after
transplantation remain to be elucidated. For a successful
transplantation, researchers have to overcome these chal-
lenges before stem cell therapy [1]. Moreover, it is very
critical to understand the biology of transplanted stem cells
and their interaction with the host tissue and regeneration
of damaged tissue at cellular level.
It seems that providing the new techniques for moni-
toring the stem cell transplantation fate is an essential
requirement for providing new opportunities in regenera-
tive medicine. Recent advances in molecular imaging and
production of new probes have provided successful non-
invasive tracking of transplanted stem cells in the living
subject [2]. Stem cell imaging can be performed through
labeling cells with probes that attach to the cells. The signal
generated from the probes can be visualized using several
imaging systems such as positron emission tomography
(PET), single-photon emission computed tomography
(SPECT), or magnetic resonance imaging (MRI).
2 Stem cells in regenerative medicine
New ideas in regenerative medicine must first be tested and
the results have to be approved before being tested in
clinical trials. Stem cells have a unique potential to develop
into different types of cells and tissues, and to maintain cell
source during early life and growth. These cells are capable
of renewing themselves and also can be induced to tissue
specific cells. Due to unique regenerative abilities of stem
cells, regenerative medicine has non-negligible potentials
for treating diseases such as heart disease, diabetes, kidney
failure, stroke, and so on. Different sources of stem cells,
such as hematopoietic, mesenchymal, adipose, embryonic,
and neural stem cells have been introduced for treatment of
various diseases. The bone marrow is the most important
source of adult stem cells, containing the hematopoietic
and mesenchymal stem cells. The adult tissues, including,
adipose, peripheral blood, lung, fetal liver and fallopian
tube are another sources for adult stem cells. Moreover,
stem cells can be taken from the inner cell mass of blas-
tocysts and umbilical cord blood [2, 3].
Different types of stem cells have been suggested for
regenerative medicine. Mesenchymal stem cells (MSCs)
are most common candidate for stem cell therapy and
clinical application. These cells have good capacity for
self-renewal and differentiation while can preserve self-
multipotency [4]. A unique feature for MSCs is
immunomodulatory properties that reduce probability of
transplant rejection [5]. These cells are found in bone
marrow and other adult people tissues and are able to
differentiate various cell types belonging to skeletal tissues,
such as adipocytes, chondrocytes, osteocytes, and car-
diomyocytes [6]. Thus, MSCs can be used for different
diseases in various tissues such as liver, the urinary, car-
diovascular, and gastrointestinal system [7].
The neural stem cells are demonstrated to divide into
progenitor cells and to develop into neurons, oligoden-
drocytes, and astrocytes. These progenitor cells are able to
migrate through the brain and spinal cord to maintain
neural cells populations. The neural stem cells have been
employed for recovery of neurons and oligodendrocytes
population within the brain for neurodegenerative diseases,
stroke and traumatic brain injury [8]. Clinical and animal
studies have been conducted to show the uses of stem cells
in cases of spinal cord injury [9, 10].
Other types of stem cells that are able to differentiate to
different types of cells are the embryonic stem cells. These
cells were used for treatment of different diseases such as
autoimmune diabetes mellitus, infertility, retinal blindness,
myocardial infarction, etc. [11].
3 The importance of MRI stem cell imaging
Clinical and animal studies have shown promising results for
stem cell regenerative medicine. Nonetheless, the results
have been unreliable, resulting in many crucial questions
regarding the feasibility of cell-based therapies. Immune
responses and cell rejection, carcinogenesis, obtain of tissues
other than desired types, and inappropriated functional
recovery are important concerns related to stem cell regen-
erative medicine. Clinical implementation of stem cell
therapywill require a better understanding of the fate of stem
cell transplantation, differentiate the desired cell type, sur-
vive the recipient after transplant, proliferate and generate
sufficient quantities of cells for making desired tissue, avoid
harming the recipient and function appropriately for the
duration of the recipient’s life [1, 12].
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So, along with stem cell research in regenerative medi-
cine, it is necessary to develop an appropriate method to
monitor the fate of implanted stem cells after being trans-
planted to the patients. The best possible way to analyze
graft–host interactions and cell survival, proliferation,
immune system reactions, and migration is a method for
monitoring safety and visualize cells in real-time during
hours to days after transplantation. To realize the promise of
novel stem cell therapy and overcome pervasive and debil-
itating diseases, scientists must make different research
strategies and possess the mentioned characteristics for an
appropriated transplantation method and to quantify their
accumulation at the target organ. These can be obtained
quantitatively and qualitatively through non-invasive
molecular imaging [13, 14]. Moreover, depictions of the
efficacy of stem cell regenerative medicine require assess-
ment of in vivo cell tracking and functional recovery. Several
molecular imaging techniques are available to follow stem
cell fate after transplantation, including PET, SPECT and
MRI [15]. Magnetically labeled cells with MRI have several
important advantages compared to other imaging technique,
including the non-invasive nature of MRI, long-term cell
tracking, lack of ionizing radiation and appropriated soft
tissue contrast and spatial resolution. Several studies have
demonstrated the feasibility and longtime duration of
tracking of MRI molecular imaging for stem cell imaging
[16]. While, other imaging techniques such as PET and
SPECT not allowing a long duration of cell tracking result in
short half time of radionuclides. The short half time of probes
of these imaging techniques like 6 h for 99 mTc-HMPAO
and 1.83 h for 18F-FDG allows tracking of cells for some
hours or day after cell injection.Moreover, ionizing radiation
of these radionuclides may cause DNA damage and
increased risk of cell death or carcinogenesis [17]. The using
ofMR contrast agents for labeling of stem cells can provide a
simple and non-invasive method for tracking of stem cells
and monitor accuracy of cell delivery to target tissue for a
long time after stem cell transplantation. These characters
have made MRI an appropriated choose for stem cell
imaging (Fig. 1).
4 MR contrast agents for stem cells imaging
Direct labeling using MR contrast agents such as micro-
particles or nanoparticles of iron oxide, gadolinium, 19F
and reporter genes has the advantages of relatively non-
toxic and high spatial resolution compared to labeling of
cells by radionuclide agents. Moreover, labeling the cells
with MR contrast agents does not affect stem cell differ-
entiation. These properties with MRI labels enable MRI
imaging to visualize the data localization and cell fate to
detect therapeutic outcome, and help to adjust the dose and
deliver route of stem cells to improve the safety and effi-
cacy of stem cell therapy [18].
The stem cell labeling with different MR contrast agents
has been used to visualize cellular homing, the efficiency
of stem cell transplantation and targeting. Several studies
have been conducted for cell labeling with magnetic
nanoparticles and have shown that these contrast agents are
generally nontoxic and do not affect stem cell division and
differentiation capacity [19]. Different factors such as type
and particle size are very important for selection of an
appropriated contrast agent. In addition to particle size,
using an appropriated labeling for contrast agent is very
important for stem cell imaging. Saito et al. [20] have
Fig. 1 Different imaging
modalities for tracing of
transplanted stem cells
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suggested that surface coating is more critical than particle
size for the optimization of a MR contrast. The most
common method for stem cell-labeling before injection is
to culture cells with desired contrast agents.
Despite several advantages, most of the contrast agents
used in MR stem cell imaging have failed to distinguish
individual cells. Thus, for the purposes of cell imaging,
such as stem cells used in cell therapy, cells must be
labeled with a potent contrast agent to distinguish these
cells from the background. Some MR contrast agents have
been adopted for verifying the delivery of therapeutic
methods after administration of stem cells [21]. The major
classes of contrast agents are iron particles, gadolinium and
perfluorocarbon (PFC) compounds contain 19F.
4.1 Iron particles
Iron particles with some micron in size (4 or 5 micron)
have most applications for labeling of the stem cells. These
particles produce a potent dark signal void in T2/T2*
weighted images. Iron particles in several types and sizes
have been used for stem cell tracking. These particles
produce a strength signal that facilitates the monitoring of
transplanted cells. By contrast to some toxic agents, iron
particles have a good biocompatibility due to natural daily
requirement of the human body and its biodegradable of
iron after entrance to body [22]. Despite their advantages,
use of iron particles, in case of overload of iron storage
may cause an increase in intracellular unbound iron,
resulting in the formation of reactive oxygen species (ROS)
through catalyzing the conversion of superoxide and
hydrogen peroxide to free-radical ions. The ROS produc-
tion can lead to oxidative damage and cell death [23, 24].
So, administered iron concentration for MR cell imaging
must be in a controlled range. Barrow et al. showed that
polymers can reduce toxicity and also protects iron core
against degeneration [25]. Paramagnetic nanoparticles,
superparamagnetic iron oxide nanoparticles (SPIONs)
particles and Ultrasmall superparamagnetic iron oxides
(USPIOs) are most important types of iron particles that
have been used for this aim.
Recently, non-toxic forms of iron compounds such as
ferumoxytol, magneto-endosymbionts, bicy-
cle[6.1.0]nonyne-modified glycol chitosan nanoparticles
(BCN-CNPs) have been tested successfully [26–29].
Among them, ferumoxytol has been found as an FDA
approved agent for clinical applications [30].
4.2 Paramagnetic and superparamagnetic iron
oxide nanoparticles (SPIONs)
Superparamagnetic or paramagnetic nanoparticles are iron
oxide particles in the range of up to 100 nm coated with
biocompatible agents such as proteins, polymers, lipids and
polysaccharides, which improve their stability and reduce
their aggregation [31]. These particles have magnetization
only in an applied magnetic field; also, they are able to
form stable colloidal suspensions for biomedical applica-
tion. The size, shape, and surface nature of SPIONs are
controllable by changing the type of the iron salt [32]. In a
magnetic field, the SPIONs have a strong magnetic sus-
ceptibility and induce fast T2/T2* relaxation.
Images obtained from Iron oxide nanoparticles are
highly sensitive for detection of single cells [33]. While
low specificity of this technique in regions with low signal
leads to reduced ability for in vivo quantification of the
signal loss [34]. These properties have made SPIONs as
one of the most popular contrast agents used in research
and clinical applications for MR imaging of cell therapy. In
an applied magnetic field, the individual moments in
SPIONs are free to align with the external magnetic field.
This feature causes the formation of a single spin, with a
net moment at least 4 orders of magnitude more than a
comparable ensemble of paramagnetic spins [35]. As
regards SPIONs can be delivered to a desired site by a
magnetic force, they are good candidates for controlling
targeting clinically.
4.3 Ultrasmall superparamagnetic iron oxides
(USPIOs)
Ultrasmall superparamagnetic nanoparticles are another
class of iron MRI contrast agents that were normally used
as negative (T2) contrast agents. USPIOs are particles with
the size smaller than 50 nm. The size of this particle type
will control the T2/T1 relaxivity time and therefore the
signal intensity in MRI. So, smaller size of USPIOs results
in lower values for the T2 relaxivity time and increases the
quality of the diagnosis. Due to small size of USPIOs, these
particles are able to avoid fast uptake by the macrophages
and the reticulum endothelial system (RES), that sustain
prolonged circulation in the bloodstream after intravenous
administration [36]. The size of the particles is a substantial
factor in clearance by the RES or through renal filtration.
Particles with a larger size than 200 nm in diameter are
generally cleared via the RES, whereas particles with a
smaller diameter than 10 nm are removed through renal
clearance system. So, particles with a size between 10 and
100 nm have the greatest circulation time and are appro-
priated for long time monitoring [37]. Iron particles have
shown, insufficient sensitivity for detection of single
labeled cells which can be considered as one of the most
important disadvantages of this contrast agent. Schellen-
berger et al. have attempted to detect single transplanted
stem cells in vitro and also mice brains. They used very
small size of iron oxide nanoparticles and images were
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obtained using a 7 T MRI instrument. Their results showed
that single cell detection can be achieved only after a high
number of labeled iron particles to injected cells. However,
in an optimized situation the detection rate was lesser than
50% [38].
4.4 Fluorine-19 (19F)
19F is another MRI contrast agent that has been used for
stem cell tracking in experimental and clinical studies. The
19F is an alternative to iron cell tracking that has been used
as an appropriated contrast agent for stem cell imaging.
The 19F is able to trace transplanted cells with a higher
specificity compared to Iron oxide nanoparticles due to low
levels of fluorine in cells [39]. The most important
advantages of 19F are the detection of only labeled cells
and no background signal from the host’s tissues observed.
Perfluorocarbon (PFC), a compound containing 19F, widely
has been used in NMR studies. PFC agents are not
metabolized by cell and are not degraded by lysosomal
enzymes. Also, PFCs do not lead to toxicity even at high
doses. A PFC nanoparticle has 200–300 nm diameter and
comprises a liquid core encapsulated and a high concen-
tration of 19F atom. PFCs have been used as 19F tracer since
the beginning of MRI for various aims such as angio-
graphic and MRS.
For cell imaging, the number of PFC probe is related to
the obtained 19F signal intensity and number of cells in
regions of interest [40]. Several studies have taken PFC
containing 19F as an appropriated MR contrast agent for
stem cell tracking. Morawski et al. [39] reported a quan-
titative assessment of PFC nanoparticles as well as a linear
relationship between the measured MR signal and the
concentration of targeted PFC nanoparticles. Gaudet et al.
have used 19F to detect the feasibility of quantifying human
and mice MSCs survival labeled with a 19F in an immune-
competent mouse host. Mice were imaged at four time
points, at day 0, 3, 9 and 16 after implantation. This study
showed the ability of 19F MR contrast agent in measuring
the number of transplanted stem cells immediately after
transplantation. However, this study has not shown a sat-
isfy signal for later times [41]. A linear relationship
between the measured signal intensity and the numbers of
targeted nanoparticles that have been investigated within
these studies. This is a significant advantage for 19F that
can be used for many purposes of stem cell imaging such as
selection of an appropriated dose and deliver route of stem
cells.
In clinical experience, PFC was tested for acute toxicity.
The obtained results didn’t show adverse effects at differ-
ent using doses. Also, the results have not shown any
evidence for active exocytosis of PFC, and the labeled cells
preserved from the reticuloendothelial system. These
results indicated PFC as an appropriated candidate for long
term and non-toxic cell tracking [42]. The use of three
dimensional compressed sensing method accelerates 19F
MRI data acquisition by at least eightfold for cell tracking
without seriously reduction in signal-to-noise ratio (SNR),
image degradation and 19F quantification accuracy [43]. A
combination of 19F and iron particles has been proposed for
detection of viable cells from dead injected cells. Authors
stated that imaging of iron-labeled macrophages in proton
density images can predict cell rejection [44].
4.5 Gadolinium (Gd)
Gd is a common contrast agent in MRI that has been used
in several experimental studies for tracking of transplanted
stem cells. While there are some concerns related to
potential toxicity of Gd such as nephrogenic systemic
fibrosis in some patients, studies have shown satisfactory
results for real time imaging of stem cells. Gd is a potent
T1-weighted contrast agent with positive signal intensity in
MRI images. In contrast to iron particles, positive signal in
Gd improves the detection and tracking of cells in low-
signal situation. Also, in hemorrhagic situations or necrotic
tissues that produce T2-weighted images, use of Gd is
preferable to dark signal contrast agents such as iron par-
ticles and 19F.
Gadolinium diethylenetriamine pentaacetic acid (Gd-
DTPA) is the most used type of Gd compound in MRI
examinations. However, some various types of Gd com-
pound such as gadolinium rhodamine dextran, gadofluorine
M, gadolinium-fullerenol and Gd-DTPA/jetPEI complexes
have been examined in several studies. An important dis-
advantage of Gd-DTPA is its inability to pass through the
stem cell membrane. Some studies have made efforts to use
other compounds containing Gd for improving cell uptake.
Tseng et al. have suggested gadolinium hexanedione
nanoparticles (GdH-NPs) to label hMSCs. High
hydrophobicity of this compound compared to Gd-DTPA
can facilitate its possession through cell membrane and
accumulation in hMSCs. As a result, the obtained signal
was more powerful [45].
An important advantage of Gd-DTPA compared to some
other contrast agents is its fast elimination in dead cells or
interstitial spaces. This can allow to separate the viable
cells from necrotic or rejected cells [46]. Considering this
feature, signal produced by Gd-DTPA is used for detection
of dead and live transplanted stem cells. Njen et al. have
shown in dead cells labeled with Gd-DTPA and SPIONs,
Gd-DTPA against SPIONs releases faster from dead stem
cells and away from SPIONs. This results in generation of
spots with T1 signal in the vicinity of the dead cells. On the
other hand, live cells did not release Gd-DTPA or SPIONs
and T1 signal was not observed in the vicinity [47].
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In vivo tracking of MSCs labeled with Gd-DTPA/jetPEI
have shown real time distribution of MSCs with the hyper-
intense signal in injured spinal cord area during 14 days
following transplantation. Histological evaluation has
confirmed that labeled MSCs by this compound could
survive in the injected area. However, there was not any
apparent relation between numbers of injected cells and
signal intensity [48].
An interesting idea for efficient uptake and high labeling
efficiency of contrast particles including Gd-DTPA is using
transfection reagent such as viral vectors, liposome, cal-
cium phosphate and others. Using liposomes has shown
better concentration and uptake of Gd by the cell mem-
brane of MSCs. Also, liposomes did not have toxic effects
on differentiation, viability or proliferation [49]. Shen et al.
have shown an effective uptake of Gd-DTPA using a non-
liposomal lipid transfection reagent into neural stem cells.
This method showed more efficient uptake and less toxicity
effect on stem cells compared to other transfection agents
such as viral vectors, liposome or calcium phosphate [50].
These studies have shown that Gd-DTPA labeled with
different carriers can be good candidate for tracing of
injected stem cells. Despite all the advantages of Gd
compounds, nephrotoxicity and nephrogenic systemic
fibrosis (NSF) are of main side effects for clinical appli-
cation. However, in recent years, some strategies have been
conducted to reduce toxicity of this contrast agent [51, 52].
For example, trimetasphere metallofullerene is a form of
Gd compounds with low toxicity which has used for stem
cell tracing with success. In this compound Gd core
encapsulated in the center of a metallofullerenes [53].
4.6 Reporter genes
In molecular biology, reporter genes are used to detect the
expression of the gene of interest and changes in tran-
scriptional rate. Also, reporter genes are capable to assess
the location of transcriptional activity of a specific protein
within living cells. In recent years, different new classes of
reporter genes have been encoded for various imaging
modalities such as PET, SPECT and optical imaging. MRI
reporter genes have unique properties among all reporter
genes used with other imaging modalities because these
reporter genes are capable to provide information about
gene function that can be combined with anatomic and
functional information [54]. MRI reporter genes embody
serial imaging, which is useful for visualization of dynamic
processes. Recent advances in MRI reporter gene tech-
niques have been able to image the cell division, prolifer-
ation, migration, and survival. Some recent studies have
been conducted to track the survival and proliferation of
pluripotent or multipotent cells injected into injured tissue
used in cell based regenerative therapies.
Alongside the increased need of molecular imaging for
regenerative medicine and stem cell imaging, a sheer
number of MRI reporter genes has been developed to
visualize the survival and proliferation of stem cells
injected into injured tissue. A number of approaches for
MRI imaging by reporter genes including, use of consti-
tutive over-expression of iron binding proteins in cells, use
of transgenic cells that express the special genes, and use of
targeted contrast agents for visualization of engineered cell
surface reporter genes has been introduced [55]. Some
types of reporter genes include iron homeostasis proteins,
reporter enzymes, and chemical exchange saturation
transfer (CEST) reporter genes [56].
Overexpression of iron-containing proteins, including
transferrin receptor was expected to increase the level of
iron in the cells, and thus causes buildup of iron within
ferritin. Over-production of the heavy chain of ferritin,
which may use in combination with the ferritin or the
transferrin receptor, leads to overload of intracellular iron
stores. The enzymes such as divalent metal transporter
(DMT1) and tyrosinase, b-galactosidase were suggested as
reporter gene for MRI. Upregulation of these enzymes
results in accumulation of paramagnetic ions and thus
generates T2 signal contrast. Reporter genes have been
used for imaging of neurogenesis, cardiac, cancer and
others [57]. Genetically, labeling of stem cells with one or
several reporter genes has unique advantages compared to
other labeling methods, because a reporter gene label
integrated in the stem cell would be transmitted to its
progeny cells, whereas signals resulting from other contrast
agents would become weaker with every cell division. This
feature allows stem cell tracking regardless of the number
of cell divisions. Moreover, the reporter genes are only
expressed by viable cells. Thus the reporter gene can be
inserted under a specific gene promoter, these contrast
agents are only visualized if the stem cell differentiates into
desired phenotype [58]. Additionally, the expression of a
reporter gene can be made dependent on the differentiation
status of a cell. So, the detection of gene reporter correlates
with stem cell viability and differentiation ability.
Pereira et al. have investigated the overexpression of
ferritin heavy chain-1 (but no transferrin receptor-1)
affected the cell’s iron homeostasis. The overexpression of
ferritin heavy chain-1 or transferrin receptor-1 didn’t cause
remarkable increases in intracellular iron content, but sig-
nificant increases were seen when these two agents were
used in combination. Also, the supplementation with iron
sources to obtain contrast is more efficient than the reporter
genes [59].
Deans et al. have shown the induction of human trans-
ferrin receptor and ferritin in mouse neural stem cell. The
transgenic cells have shown a significant increase in T2* at
1.5 and 7 T. The transplantation of these cells into mouse
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brain showed increase in contrast with surrounding tissue
on T2*-weighted images. While the viability of cells was
not decreased, increase in ROS was investigated [60]. The
adding of iron to the culture medium of transferrin and
ferritin reporter has shown that this method is more
effective to obtain a more appropriate contrast compared to
the use of reporter genes alone [59]. In despite of several
advantages of reporter genes, low signal intensity in these
contrast agents compared to others is the most important
concern (Table 1).
Because, low contrast is the main disadvantage of
reporter genes for tracking of stem cells, scientists have
tried to improve MRI signals using novel or dual reporter
gene imaging. Development of novel reporter genes such
as T cell immunoglobulin and mucin domain containing
protein 2, adenoviral vector encoding ferritin heavy chain
and magneto-endosymbionts are some example that have
been produced in recent years [61–63]. In a study by Guo
et al. studied tracing of MSCs in rabbit using two reporter
genes including ferritin heavy subunit and transferrin
receptor. Their results indicated that dual reporter genes
augment the content of produced iron in MSCs without any
effect on biological properties of transplanted cells. Also,
MRI contrast increased and homing and migration of
MSCs detection was improved [64]. In addition, some
studies have conducted to provide better understanding of
location of transplanted cells using dual modality reporter
genes. For example, the tyrosinase reporter gene has been
used to trace MSCs to animal infarction cardiac using MRI,
ultrasound and PET imaging [65]. Dual-imaging reporter
genes have been used for MRI and fluorescence too [66].
5 MR stem cell imaging in different organs
Stem cell therapy has been recommended for treatment of
different disorders in various organs such as cardiovascu-
lar, nervous, gastrointestinal and urinary systems, and also
joints. The most important indications for stem cell therapy
and tracking in experimental and clinical studies include
stroke, neurodegenerative diseases, trauma, diabetes, mul-
tiple sclerosis (MS) and others.
5.1 Cardiovascular system
Cardiovascular disorders such as myocardial infarction
(MI) are the major cause of morbidity and mortality in the
world [67]. Although the most effective treatment is car-
diac transplantation, the difference between organ supply
and demand restricts its applicability. Another treatment
modality is cellular cardiomyoplasty that includes systemic
(intravenous) and local (intramyocardial, intracoronary)
delivery of skeletal myoblasts, fetal/neonatal cardiomy-
ocytes, embryonic stem cells, hematopoietic stem cells or
MSCs. Regenerative medicine is a promising method for
functional recovery in MI patients. This modality effort
into repopulating the region of infarction enhances cardiac
function with viable cardiomyocytes. MRI as a noninvasive
imaging technique could use the assessment of migration,
survival, and differentiation condition of implanted stem
cells in infarcted myocardium [68–70].
The results obtained from preclinical and some clinical
studies have indicated that stem cell therapy may improve
myocardial function. However, there are questions espe-
cially about appropriated method for injection of cells and
filtration of stem cells into the infarcted area. Li et al. have
evaluated cardiac function after injection of bone marrow
stromal cells with a reporter gene in myocardial infarction
in rat model. Tracking of delivered cells with MRI has
shown that intramyocardial cell implantation compared to
intravenous or Intra-aortic implantation results in better
localization of cells in the heart. While, signal loss after
48 h was remarkable [71]. Campan and colleagues have
reported the use of ferritin heavy chain as a reliable
reporter gene to track injected stem cells in a rat model of
myocardial infarction. The T2* gradient echo sequence
showed iron-accumulating tissue in hearts treated with
ferritin reporter gene for 4 weeks after infarction. Prussian
Table 1 Contrast agents for MR stem cell imaging
Contrast agents Advantages Disadvantages
Iron particles (include Superparamagnetic iron
nanoparticles, Iron oxide nanoparticles and
USPIO)
High sensitivity, potent
signal
ROS production, decrease in cell proliferation, uptake by the
mononuclear phagocyte system, negative signal, partial
volume artifact
Fluorine-19 High specificity, linearity
relationship to cell
numbers
Low sensitivity, low signal to noise ratio per unit scan time
Gadolinium Differentiation between live
and dead cells, positive
signal
Nephrotoxicity, Nephrogenic systemic fibrosis (NSF)
Reporter genes Long term tracking of cells Limited Contrast, effect on Iron homeostasis, ROS production
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blue staining confirmed that the myocardial function and
differentiation into cardiac muscle lineage, endothelial, and
smooth muscle were not affected by ferritin overexpression
[72]. He et al. have detected the noninvasively transplanted
MSCs labeled with SPIO for 4 weeks after injection of
labeled cells. Histopathological examinations showed that
the injected cells were surviving in the MI heart [73]
(Fig. 2).
5.2 Urinary system
In urology, novel applications of regenerative medicine and
tissue engineering were used for many disorders, and the
researches in this field have increased dramatically over the
past decade. MRI is a complementing and contending
modality for studies of stem cell in urology. MRI with a
physical labeling method or alone can be applied to assess
migration and survival of transplanted stem cells in bladder
dysfunction models and prostate cancer. In addition, stud-
ies suggest potential efficiency for use on urethral sphincter
dysfunction and erectile dysfunction [74–76].
Many studies reported the efficacy of using stem cell in
treatment of bladder dysfunction. Yun and Ja reported
similar livability of SPION-labeled MSCs compared to
unlabeled cells. MSCs labeled with SPIOs underwent
normal adipogenic, chondrogenic, and osteogenic differ-
entiation. MRI signal intensity in the regions of SPION-
labeled MSCs in rabbit and rat bladders decreased and was
limited locally. MRI showed that SPIO-labeled MSCs
injected into the bladder could be observed for at least
12 weeks after injection [77]. In another study, Lee et al.
demonstrated that MR images were beneficial for moni-
toring transplanted MSCs in bladder outlet obstruction
induced bladder dysfunction. T2-weighted MR images
were taken instantly after transplant of MSCs labeled with
SPIONs and at 4 weeks after transplantation. T2-weighted
MR images demonstrated a clear hypo-intense signal
induced by these cells. TGF-b expression and collagen
increased after bladder outlet obstruction, and after MSCs
transplantation, the expression of both returned to original
levels [78]. In another study, Lee et al. [79] used MRI to
monitor the migration of genetically modified stem cells
after labeling these cells with fluorescent magnetic
nanoparticles.
In regarding to urethral sphincter dysfunction, Riviere
et al. labeled muscle implants with anionic magnetic
nanoparticles. They investigated the biocompatibility of
the labeling procedure and its efficiency for MRI follow-up
of cell therapy in a model of female pig. These nanopar-
ticles were adsorbed on the implant surface of myogenic
precursor cells and were magnetically labeled within the
implants. They showed magnetic labeling did not affect
cell differentiation or proliferation. In addition, detection of
auto graft in vivo by MRI was possible up to 1 month [80].
Song et al. suggested that MRI can be applied to eval-
uate the long-term therapeutic potential of MSCs for
Fig. 2 Serial bioluminescence and MR imaging of transplanted H9c2
cells. MR imaging indicates a high hypointense signal of transplanted
cells in the myocardium. The scope and intensity of signal decreases
with time. Transplantation of cells has confirmed by bioluminescence
imaging. Adopted from Cromer Berman et al. [103], with permission
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treatment of erectile dysfunction. MSCs labeled with
SPIONs injected into the corpus cavernosa of rabbits and
rats were evaluated by MRI. MRI signal intensity at the
area of these cells in the rabbit and rat corpus cavernosa
decreased and was limited locally. MRI showed that the
MSCs could be seen for at least 12 weeks’ post- injection
into the corpus cavernosum [81].
5.3 Nervous system
The experimental studies explored the promising results of
stem cell therapy for neurodegenerative diseases and
improvement in neural functioning [82]. Stem cell therapy
for neural system can alleviate deficits in experimental
stroke model in several studies. Molecular imaging of
different types of stem cells such as MSCs, bone marrow
hematopoietic stem cells and mouse embryonic stem cells
(ESCs) through MRI can monitor location, size, tissue
repair, stem cell fate, and responses to transplanted stem
cell therapy to brain for long time after transplantation
[83, 84]. In contrast to other tissues, cellular turnover in the
nervous system occurs in a much lower rate and cannot
completely restore function. After incidence of stroke,
newly generated cells from stem cells migrate to the
damaged area of the brain. However, survival of brain stem
cells in the damaged site is jeopardized.
Neurological disorders such as cerebral ischemia or
mentioned neurodegenerative diseases result in a mobi-
lization of progenitor cells and their migration towards the
damaged areas. In most cases, the intrinsic response is not
sufficient to lead to the functional recovery and to result in
a permanent disorder. In the last decade, evidence of
neurogenesis probability in the human adult brain has
provided the basic scientific hypothesis of (stem) cell
transplantation therapy in various neurological disorders
including; Parkinson disease, multiple sclerosis (MS), and
stroke, to improve neurological defects and relieve dis-
ability. It is suggested that regenerative medicine through
transplant of stem cells is able to restore the injured area.
After transplantation, neural stem cell progeny may sur-
vive, proliferate, differentiate a specific lineage and restore
the stroke area or die. The fate of transplanted cells to
foster long-lasting regeneration is highly dependent on cell
delivery, donor cell properties, and graft–host interactions
[85, 86].
The MR tracking of injected stem cells in the brain has
been conducted by several studies. For the first time, rel-
evant studies were reported in 2007 by Sykova and Jen-
delova. They followed the embryonic stem cells (ESCs)
and MSCs labeled with superparamagnetic contrast agents
for imaging the progenitor cells transplanted into rats with
a cortical or spinal cord lesion. They considered MR
imaging of cell labeled with iron oxide nanoparticles as a
useful method for evaluation of migration of transplanted
progenitor cells toward a lesion site [87]. Nowadays,
imaging of labeled progenitor stem cells with MRI contrast
agents such as SPIO or USPIO is already used in experi-
mental models of neurological diseases. In recent years,
some studies have been conducted to trace injected stem
cells real time and immediately after injection [88–90].
Walczak et al. showed that high-speed MRI can detect the
intravascular distribution of SPIO-labeled stem cells.
Moreover, they showed that using this instrument can trace
homing of injected cells. This property is very important
because provide the opportunity for other interventions in
the case of unsuccessful homing [91].
5.3.1 Trauma
Zhu et al. have showed cell migration by MRI for neural
stem cells injected into patients with brain trauma. Their
investigation has shown the presence of neural stem cells
(NSCs) for up to 3 weeks after injection [92]. Callera et al.
showed that MRI is able to detect administrated labeled-
CD34(?) cells with magnetic nanoparticles for 35 days
after cell transplantation and also showed the migration of
cells toward the damaged site in patients with chronic
spinal cord injury [93]. Guzman et al. showed an average
of 51.3% of human NSCs at 5 weeks after cell injection.
They did not investigate adverse effects of MR contrast
agents on survival, migration, and differentiation of NSCs
[16].
5.3.2 Stroke
There are two types of stroke, including hemorrhagic and
ischemic stroke. Ischemic stroke is themost common type of
brain stroke. Stroke is one of the most common causes of
human disability caused by irreversible neurological dam-
ages. Several studies have reported SPIO-based MRI of
grafted cells in the course of migration in stroke experi-
mental models. Stroh et al. have designed an experimental
study to track injected mononuclear cells (MNCs) in the
ischemic mouse brain using 7 T MRI. Brain ischemia gets
filamentous by occlusion of the middle cerebral artery and
reperfusion. MNCs were labeled with very small super-
paramagnetic iron-oxide particles and T2 and T2* sequen-
ces were generated and optimized to monitor engraftment
and migration of injected cells into the ischemic brain. The
region of interest (ROI) data of the experimental animal
showed the appearance of the hypointense region in ische-
mia brain areas [94]. In a clinical study, injection of
umbilical cord blood-derived stem cells labeled with SPIO
to a patient suffering global cerebral ischemia showed
promising results. In this study, transplanted stem cells were
traced for 4 months after injection [95].
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5.4 Pancreas
Diabetes mellitus type 1 or insulin-dependent diabetes is a
chronic pancreatic disease that is associated with the
autoimmune destruction of the b-cells in the pancreas. The
lack of insulin is along with this autoimmune disease that
leads to increased blood and urine glucose. Administration
of insulin is essential to prevent dangerous effects such as
blindness, nephropathy, foot ulcer and amputation. Stem
cell therapy is a new strategy for replacement of insulin-
producing cells. Adult and embryonic stem cells can be
differentiated from b-cells under special conditions.
Hematopoietic stem cells, pancreas and liver resident stem
cells might give rise to pancreatic endocrine phenotype.
The cells derived from adult tissues are differentiated into
insulin-secreting cells and alleviate diabetes mellitus in
rodents [96, 97]. Dor et al. [98] have investigated that
differentiated b-cells in pancreas retain proliferative
capacity. Moreover, this cell type can account for turnover
and expansion throughout a mouse’s life.
Immune rejection and nonimmunological events such as
ischemia, hypoxia and hyperglycemic microenvironment
may lead to significant graft loss and fail to make progress
in treatment. So, noninvasive monitoring of fate of the
transplanted cell and assessing the function of islets graft
following transplantation are a crucial issue for diabetes
stem cell therapy. Tang et al. have investigated improve-
ment in islet repaired by MSCs differentiation and change
in pancreatic microcirculation by in vivo real-time MRI
imaging. In this study pig MSCs were cultured and labeled
with SPIO. Then, labeled cells were injected into the
pancreas of diabetic pigs through targeted intervention. The
MR imaging showed the implantation of MSCs can par-
tially repair damaged islet b-cells and restore the function
of pancreas in type 1 diabetes [99]. Zhang et al. have
revealed that under in vitro situation, b-cells can label with
polyvinylpyrrolidone-coated super paramagnetic iron oxide
nanoparticles (PVP-SPIO) and detected by MRI. In vivo
study confirmed cell labeling efficiency after renal sub-
capsular transplantation [100].
5.5 Joints
Cartilage lesions such as osteoarthritis or acute trauma
under mechanical or biochemical stress are major clinical
problems due to poor intrinsic repair capacity of these
tissues. During these situations, the long term upregulation
of proinflammatory cytokines and mediators degrades the
structure of the articular cartilage. Evidences have proved
that stem cell therapy has potential for chondrogenic dif-
ferentiation and repair of cartilage defect [101]. Jing et al.
have shown that MSCs can be efficiently labeled with
SPIO to visually track SPIO-labeled MSCs injected into the
knee joint of rabbit models for cartilage defects. Then GRE
T2*-weighted MR imaging at 1, 4, 8 and 12 weeks after
cell injection done. The SPIO contrast agent did not affect
cell viability, proliferation and differentiation. Histo-
chemical staining confirmed the data obtained from MRI
imaging [102] (Table 2).
6 Conclusion
Stem cell transplantation is currently being evaluated for
treatment of many diseases. There is a grave need to
determine of cell migration, homing, distribution and dif-
ferentiation of transplanted stem cells, and finally selection
of appropriated methods for delivery of optimal stem cell
type. Tracking the injected stem cells with MRI is a non-
invasive and relatively safe method and is able to visualize
transplanted cells for long term tracing of labeled stem
cells. Advances in synthesis of new contrast agent com-
pounds facilitate safe cell tracking for clinical applications.
The possible clinical use of stem cell therapy for several
diseases can make MR stem cell imaging as a non-negli-
gible modality for evaluation of transplant fate.
Table 2 Summary of different studies for stem cell tracing using MRI contrast agents
Route Transplanted cell type Contrast agent Targeted organ Time of tracing References
Chinese mini swine MSCs SPIO Heart 4 weeks [73]
Rat Swine cardiac progenitor cells Ferritin heavy chain Myocardial 4 weeks [72]
Rat MSCs SPIO Bladder 12 weeks [81]
Rat ESCs and MSCs Iron oxide nanoparticles Cortical and spinal cord More than 1 month [87]
Human CD34(?) Magnetic nanoparticles Spinal cord 35 days [93]
Mouse MNCs SPIO Brain 5 weeks [94]
Pig MSCs SPIO Pancreas 6 weeks [99]
Rabbit MSCs SPIO The knee joint 12 weeks [102]
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